Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Autogenic and Allogenic NK Immunotherapy in Recurrent Solid Tumors
NCT02853903Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of HANK cells in malignant solid tumor, sponsored by Fuda Cancer Hospital. Started Jul 2016; status: completed.
02
Drugs
HANK cells
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT02853903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02853903.